Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICASSO trial
2023-505254-17-00Phase 4Authorised
- Sponsor
- Diakonhjemmet Sykehus
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of triamcinolone acetonide and sodium chloride in osteoarthritis (OA) (3 arms), sponsored by Diakonhjemmet Sykehus. Primary endpoints: Change in thumb base joint pain during activities last 24 hours on a Numeric Rating Scale (NRS) after 4 weeks and Change in thumb base joint pain during activities last 24 hours on a Numeric Rating Scale (NRS) after 12 weeks. Planned start Nov 2023; status: authorised.
02
Drugs
triamcinolone acetonidesodium chloride
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2023-505254-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505254-17-00.